198 related articles for article (PubMed ID: 36431875)
1. Dihydrotanshinone I Inhibits the Proliferation and Growth of Oxaliplatin-Resistant Human HCT116 Colorectal Cancer Cells.
Wang M; Xiang Y; Wang R; Zhang L; Zhang H; Chen H; Luan X; Chen L
Molecules; 2022 Nov; 27(22):. PubMed ID: 36431875
[TBL] [Abstract][Full Text] [Related]
2. Prostaglandin F
Wang YJ; Xie XL; Liu HQ; Tian H; Jiang XY; Zhang JN; Chen SX; Liu T; Wang SL; Zhou X; Jin XX; Liu SM; Jiang HQ
World J Gastroenterol; 2023 Oct; 29(39):5452-5470. PubMed ID: 37900995
[TBL] [Abstract][Full Text] [Related]
3. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145.
Gao R; Fang C; Xu J; Tan H; Li P; Ma L
Arch Biochem Biophys; 2019 Mar; 663():183-191. PubMed ID: 30639170
[TBL] [Abstract][Full Text] [Related]
4. IFI6 Downregulation Reverses Oxaliplatin Resistance of Colorectal Cancer Cells by Activating the ROS-Induced p38MAPK Signaling Pathway.
Huang C; Zhou T; Ma L; Zhao S
Biol Pharm Bull; 2023; 46(1):26-34. PubMed ID: 36596524
[TBL] [Abstract][Full Text] [Related]
5. Shikonin potentiates therapeutic efficacy of oxaliplatin through reactive oxygen species-mediated intrinsic apoptosis and endoplasmic reticulum stress in oxaliplatin-resistant colorectal cancer cells.
Zhang Z; Shen C; Zhou F; Zhang Y
Drug Dev Res; 2023 May; 84(3):542-555. PubMed ID: 36779379
[TBL] [Abstract][Full Text] [Related]
6. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer.
Huang C; Wang M; Wang J; Wu D; Gao Y; Huang K; Yao X
Biochem Pharmacol; 2021 Jul; 189():114390. PubMed ID: 33359068
[TBL] [Abstract][Full Text] [Related]
7. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.
Zhou H; Lin C; Zhang Y; Zhang X; Zhang C; Zhang P; Xie X; Ren Z
Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 28217977
[TBL] [Abstract][Full Text] [Related]
8. [Synergistic effect of polysaccharide from
Li P; Yuan P; Que Y; Liu X; Wang G
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Apr; 41(4):504-513. PubMed ID: 33963708
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
Hsu HH; Chen MC; Baskaran R; Lin YM; Day CH; Lin YJ; Tu CC; Vijaya Padma V; Kuo WW; Huang CY
J Cell Physiol; 2018 Jul; 233(7):5458-5467. PubMed ID: 29247488
[TBL] [Abstract][Full Text] [Related]
10. Significance of Notch and Wnt signaling for chemoresistance of colorectal cancer cells HCT116.
Kukcinaviciute E; Jonusiene V; Sasnauskiene A; Dabkeviciene D; Eidenaite E; Laurinavicius A
J Cell Biochem; 2018 Jul; 119(7):5913-5920. PubMed ID: 29637602
[TBL] [Abstract][Full Text] [Related]
11. Unraveling the immune landscape and therapeutic biomarker PMEPA1 for oxaliplatin resistance in colorectal cancer: A comprehensive approach.
Zhang Z; Lu T; Zhang Z; Liu Z; Qian R; Qi R; Zhou F; Li M
Biochem Pharmacol; 2024 Apr; 222():116117. PubMed ID: 38461903
[TBL] [Abstract][Full Text] [Related]
12. P53‑microRNA interactions regulate the response of colorectal tumor cells to oxaliplatin under normoxic and hypoxic conditions.
Zhang J; Li C; Sun L; Sun D; Zhao T
Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37921068
[TBL] [Abstract][Full Text] [Related]
13. Dihydromyricetin reverses MRP2-induced multidrug resistance by preventing NF-κB-Nrf2 signaling in colorectal cancer cell.
Wang Z; Sun X; Feng Y; Wang Y; Zhang L; Wang Y; Fang Z; Azami NLB; Sun M; Li Q
Phytomedicine; 2021 Feb; 82():153414. PubMed ID: 33461143
[TBL] [Abstract][Full Text] [Related]
14. Kruppel-like factor 5 enhances proliferation, lipid droplet formation and oxaliplatin resistance in colorectal cancer by promoting fatty acid binding protein 6 transcription.
Zuo Q; Xu Q; Li Z; Luo D; Peng H; Duan Z
Anticancer Drugs; 2023 Nov; 34(10):1171-1182. PubMed ID: 37067981
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis.
Wang H; Li H; Zhang L; Yang D
Biomed Pharmacother; 2018 Oct; 106():1607-1615. PubMed ID: 30119236
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor potential of 15,16-dihydrotanshinone I against breast adenocarcinoma through inducing G1 arrest and apoptosis.
Tsai SL; Suk FM; Wang CI; Liu DZ; Hou WC; Lin PJ; Hung LF; Liang YC
Biochem Pharmacol; 2007 Dec; 74(11):1575-86. PubMed ID: 17869226
[TBL] [Abstract][Full Text] [Related]
17. Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin in Human Colorectal Cancer Xenografts in Nude Mice.
Li X; Xia L; Ouyang X; Suyila Q; Su L; Su X
Protein Pept Lett; 2019; 26(7):512-522. PubMed ID: 30950338
[TBL] [Abstract][Full Text] [Related]
18. Low-dose orlistat promotes the therapeutic effect of oxaliplatin in colorectal cancer.
Zhang Q; Zhou Y; Feng X; Gao Y; Huang C; Yao X
Biomed Pharmacother; 2022 Sep; 153():113426. PubMed ID: 36017794
[TBL] [Abstract][Full Text] [Related]
19. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y
Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496
[TBL] [Abstract][Full Text] [Related]
20. MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells.
Liang H; Xu Y; Zhang Q; Yang Y; Mou Y; Gao Y; Chen R; Chen C; Dai P
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):725-736. PubMed ID: 30861353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
